962
Participants
Start Date
September 6, 2019
Primary Completion Date
August 5, 2021
Study Completion Date
August 5, 2021
Norgestrel 0.075 mg tablets
"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
HRA Pharma Investigational Site 1013, New York
HRA Pharma Investigational Site 1037, The Bronx
HRA Pharma Investigational Site 1031, The Bronx
HRA Pharma Investigational Site 1030, Bronxville
HRA Pharma Investigational Site 1025, Philadelphia
HRA Pharma Investigational Site 1036, Lafayette Hill
HRA Pharma Investigational Site 1014, Rosedale
HRA Pharma Investigational Site 1015, Burlington
HRA Pharma Investigational Site 1018, Griffin
HRA Pharma Investigational Site 1023, Dalton
HRA Pharma Investigational Site 1008, Homewood
HRA Pharma Investigational site 1012, Birmingham
HRA Pharma investigational site 1016, Clarksville
HRA Pharma Investigational Site 1002, South Charleston
HRA Pharma Investigational Site 1003, Saint Francis
HRA Pharma Investigational Site 1011, Andover
HRA Pharma Investigational Site 1006, Elk River
HRA Pharma Investigational Site 1020, Saint Louis Park
HRA Pharma Investigational Site 1022, Houston
HRA Pharma Investigational Site 1001, Houston
HRA Pharma Investigational Site 1033, Aurora
HRA Pharma Investigational Site 1040, Salt Lake City
HRA Pharma investigational site 1024, Mapleton
HRA Pharma Investigational Site 1032, Phoenix
HRA Pharma Investigational Site 1038, Mesa
HRA Pharma Investigational Site 1009, Albuquerque
HRA Pharma Investigational Site 1034, Los Angeles
HRA Pharma Investigational Site 1029, Los Angeles
HRA Pharma Investigational Site 1028, Los Angeles
HRA Pharma Investigational Site 1039, Downey
HRA Pharma Investigational Site 1027, Cerritos
HRA Pharma investigational site 1035, Long Beach
HRA Pharma Investigational Site 1017, Long Beach
HRA Pharma Investigational Site 1007, Albuquerque
HRA Pharma Investigational Site 1021, Enumclaw
HRA Pharma Investigational site 1005, Seattle
HRA Pharma Investigational site 1010, Snohomish
HRA Pharma Investigational Site 1019, Framingham
Lead Sponsor
HRA Pharma
INDUSTRY